datt wars dann auch hier für mir.
bei boxenbauer leicht und locker auf platz fuffzich.
bei happy nu leicht und locker richtung platz zwanzich.
richtich geile neg-news-konsoli- wochen bei mich.
The stock (RHEO:
occulogix inc com
RHEO 4.58, -8.17, -64.1%) dropped $8.20, or 65%, to $4.50 in morning trades on heavy volume of 12.3 million.
The news also weighed on OccuLogix majority owner TLC-Vision (TLCV:
The sell-off was sparked by news that the phase III MIRA-1 trial of the company's RHEO system missed its primary endpoint, failing to demonstrate a statistically significant difference between the treated group and the placebo control group after 12 months.
The measure was mean change of Best Spectacle-Corrected Visual Acuity using the Early Treatment Diabetic Retinography Scale.
The company noted that the treated group did demonstrate a positive response but said what it termed the "anomalous response" of the control group was the principal reason for the trial's failure.
Toronto-based OccuLogix now plans to evaluate the implications of the data on its application for marketing approval for the RHEO system from the Food and Drug Administration.
TLC-Vision, headquartered in St. Louis, is an eye-care services provider. The company posted revenue of $200 million for the nine months ended Sept. 30
da sach ich doch leicht und locker:
pech im spiel - glück i.............:-)